Overview

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Status:
Completed
Trial end date:
2016-06-22
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome.
Phase:
Phase 4
Details
Lead Sponsor:
Technische Universität München
Treatments:
Amisulpride
Antipsychotic Agents
Benperidol
Bromperidol
Clopenthixol
Fluphenazine
Fluphenazine depot
Fluphenazine enanthate
Fluspirilene
Haloperidol
Olanzapine
Paliperidone Palmitate
Perazine
Perphenazine
Pimozide
Quetiapine Fumarate
Risperidone
Sertindole
Sulpiride
Sultopride
Thioridazine
Ziprasidone